11/16/26 - NVDA quarter going to stink?
11/16/26 - NVDA quarter going to stink?
YouTube8 hr 45 min
Watch on YouTube
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
  • Consider reducing or avoiding NVIDIA (NVDA) exposure ahead of earnings; weak guidance, China-related sales restrictions, and financing concerns are key near-term risks, though the discussion provided no price target.
  • Treat weakness in AMD, Micron (MU), and other AI-hardware stocks as a reason to reassess each company’s fundamentals—not as an automatic buying opportunity, since no recovery outlook was established.
  • Approach AI infrastructure companies such as CoreWeave (CRWV) and Nebius (NBIS) cautiously; financing needs and returns on costly computing capacity remain key risks.
Detailed Analysis

NVIDIA (NVDA)

  • The central concern was the upcoming earnings guidance. The host expected a potentially weak outlook, citing possible removal of Singapore-linked revenue (described as largely China-related), restrictions on advanced-chip sales to China, and an end to “circular financing.”
  • The host said, “I would sell” and that he would be scared of holding NVIDIA ahead of the report. He warned that weak next-quarter guidance could cause a dramatic drop.
  • The stock moved sharply during the broadcast, trading around $155–$162 and at points falling roughly 4–5%. Those were live prices, not price targets.
  • The discussion also raised uncertainty about leadership: participants debated whether Jensen Huang might return, but a later headline said that was unlikely. The host viewed a weak interim CEO as a concern, while others argued NVIDIA’s business and chips remained strong.
  • There were opposing views in the chat: some participants described the sell-off as overdone or bought shares, while others expected further downside. These were opinions, not a consensus forecast.

Takeaways

  • Treat the earnings guidance and commentary on China-related sales and financing as key near-term catalysts; the transcript does not establish how much of the reported revenue is actually at risk.
  • The discussion highlights both company-specific uncertainty and broader AI-investment sentiment. Avoid treating intraday price moves or chat predictions as reliable forecasts.

Semiconductor Stocks and AI Hardware

  • Semiconductor shares sold off alongside NVIDIA. During the broadcast, AMD was down about 4–5%, Micron (MU) about 7%, and SanDisk (SNDK) about 6–9% at various points. Coherent (COHR), Marvell (MRVL), and Lumentum (LITE) were also reported down sharply.
  • The host said compute and memory could remain an exciting long-term trend, but expressed uncertainty about whether individual companies such as Micron or Marvell would recover.
  • The discussion noted that specialized AI chips and alternatives to GPUs—including TPUs and other parallel accelerators—could also be used. It did not provide a clear forecast for how much market share they might take.

Takeaways

  • A downturn in NVIDIA sentiment may affect other chip and hardware companies, even when their individual outlooks differ.
  • Consider evaluating memory, networking, and optical-component businesses separately rather than assuming they will move in lockstep with NVIDIA.

AI Infrastructure and Neoclouds

  • The host was bearish on SpaceX’s cloud-computing business, describing it as a neocloud that rents GPU capacity. He said he was more positive on SpaceX’s telecom-related business than on the cloud side.
  • He called Nebius (NBIS) “dog shit” and said he was less bullish on SambaNova. The discussion also named AI-chip or compute companies including Etched, D-Matrix, Neurophos, Positron, and Groq.
  • Participants raised the risk that neocloud companies could face financing pressure if NVIDIA-related financing arrangements and customer prepayments become less available. CoreWeave (CRWV) was discussed in that context, including a bearish case involving capital constraints and weak returns on infrastructure investment.
  • The host said he changes his views on AI infrastructure frequently, reflecting substantial uncertainty rather than a settled sector call.

Takeaways

  • AI demand does not automatically translate into attractive returns for every company building or renting computing capacity. Financing needs, customer commitments, and returns on expensive infrastructure are important areas to examine.
  • The comments on individual companies were strongly opinionated and did not include detailed financial analysis; treat them as prompts for further research, not as a complete investment case.

Eli Lilly (LLY)

  • The host said he was not long Lilly at the time. He cited approximately $17 billion in GLP-related revenue in the prior quarter, up from roughly $16.2 billion, and said Lilly’s revenue had grown 36% in the most recent quarter.
  • He discussed forecasts of about $65 billion in revenue followed by $80 billion in 2027, while noting that estimates could range from $85 billion to $90 billion. He questioned whether GLP drugs could sustain growth indefinitely and whether the market could eventually saturate.
  • The discussion cited about $41 billion of net debt and examined a valuation scenario using an 8% discount rate. Under one set of assumptions, that produced a value of about $1,200 per share; the host described the shares as fairly valued or slightly overvalued if GLP sales persist, but said the conclusion depended heavily on future drug sales.
  • The host discussed retatrutide, saying Lilly was expected to file in Q1. He also considered a scenario where it became a major drug, while emphasizing uncertainty about how it would affect sales of existing GLP medicines and how the revenue curve would develop.

Takeaways

  • Lilly’s outlook, as discussed, depends heavily on the scale and durability of GLP-drug revenue and on the success of future products such as retatrutide.
  • The valuation figures were scenario-based, not a firm price target. Investors should pay attention to sales growth, competitive dynamics, debt, and the assumptions behind long-term forecasts.

Teva Pharmaceutical Industries (TEVA)

  • In a replayed interview, investor Stan Druckenmiller described Teva as a generic-drug company trading at about six times earnings when his team became interested.
  • The interview highlighted a strategy shift toward biosimilars and some non-generic drugs, along with operating-efficiency efforts under CEO Richard Francis.
  • The speaker said the stock had risen from about $16 to $32 over roughly six or seven months and that its valuation had expanded to around 11.5–12 times earnings. He attributed the re-rating to investors recognizing the business transition.

Takeaways

  • The Teva example illustrates how a company’s strategy and product mix can change investor perceptions and valuation.
  • The interview was an anecdote about an investment thesis, not a recommendation for Teva at its current price.

CG Oncology (CGON)

  • The host reviewed data for an intravesical gene therapy targeting non-muscle-invasive bladder cancer. He described the recurrence-free-survival result as “nice data” and cited a hazard ratio of 0.32.
  • He also said the data appeared to have been highly expected: the stock had traded around $100 earlier in the day and was later around $80, without a sustained positive reaction.

Takeaways

  • Clinical results can look encouraging while a stock still falls, especially when investors had already anticipated the news.
  • For a clinical-stage biotech, assess the full study design, safety data, durability, and next regulatory or clinical milestones; the transcript did not provide those details.

Moderna (MRNA) and BioNTech (BNTX)

  • The host said Moderna was not a long position for him and noted that its share price had fallen from roughly $280 to about $215.
  • When asked to compare Moderna with BioNTech, he said they were “very different companies” and mentioned BioNTech’s PD-L1 work. He said he had no position in BioNTech.

Takeaways

  • The discussion did not present a clear bullish or bearish investment thesis for either company.
  • The sharp Moderna price move was cited as context, not as a valuation signal or price target.

Novo Nordisk (NVO)

  • The host said he was bearish, more or less, on Novo Nordisk. The transcript did not include a detailed explanation for that view.

Takeaways

  • The negative view was brief and unsupported by specific company analysis in the discussion, so it is not enough on its own to form an investment case.
  • Compare product performance, competitive positioning, and valuation independently before drawing conclusions.

Tarsus Pharmaceuticals (TARS)

  • The host said he had a sizable short position in Tarsus Pharmaceuticals. The transcript did not provide the reasoning behind the position.
  • A participant suggested selling calls, but no supporting analysis or specific terms were given.

Takeaways

  • The short position is a specific disclosure, but the lack of a stated thesis makes it difficult to assess.
  • Short positions can have substantial risk if the stock rises; do not infer a price target or expected catalyst from this segment.

Bitcoin (BTC) and Cryptocurrency

  • The host said he was kind of bearish on Bitcoin and separately said he did not like crypto. He did not give a price target, timeline, or detailed rationale.

Takeaways

  • The transcript conveys a negative sentiment, not a substantiated valuation analysis.
  • No specific crypto trade or recommendation was provided.

Robinhood Markets (HOOD)

  • The host said Robinhood had been “smoked” and asked whether it could have fallen close to 50%. He did not offer a clear view on whether it was a buy or a sell.
  • A participant in the chat later said they viewed the stock as a long, but that was a participant’s opinion rather than the host’s.

Takeaways

  • The discussion points to substantial share-price volatility but offers little analysis of Robinhood’s business outlook or valuation.
  • Distinguish the host’s uncertainty from the more bullish chat comment; neither provides a specific price target.

Meta Platforms (META)

  • A participant in the chat described Meta as attractive, citing its durability and founder-CEO leadership. This was a participant’s view, not a developed thesis from the host.

Takeaways

  • The positive comment highlights leadership and business resilience as investment considerations, but the transcript provides no valuation analysis or recommendation.

Market and Portfolio-Flow Signals

  • The broadcast included a report that Bridgewater reduced its SPY and IVV holdings and sold more than 1 million shares each of NVIDIA and Amazon (AMZN) in the third quarter.
  • It also reported that the Gates Foundation Trust cut its Berkshire Hathaway (BRK.B) stake by 15.3%. These were reported portfolio changes, not statements of the investors’ reasons.
  • The host described a broad market sell-off, with the S&P 500 ETF (SPY) down around 2% at one point and weakness across technology and other growth-oriented shares.

Takeaways

  • Large-investor selling is useful context, but it does not establish why the shares were sold or predict what the market will do next.
  • The discussion suggests monitoring broad market conditions alongside company-specific catalysts, particularly when several sectors are selling off together.
Ask about this postAnswers are grounded in this post's content.
Video Description
let's get this $
About Martin Shkreli
Martin Shkreli

Martin Shkreli

By @realmartinshkreli

Investing, music, science, math, technology, programming, medicine and more!